Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis
- PMID: 22451237
- DOI: 10.1245/s10434-012-2328-0
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis
Abstract
Background: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer that has rarely been reported in large-scale clinical studies. The aim of this study was to clarify the clinical features, treatment modalities, and prognosis of cHCC-CC.
Methods: Included in this study were 113 patients who were histologically diagnosed as having Allen type C cHCC-CC, 103 of whom received liver resection, 6 transarterial chemoembolization treatment, 3 radiofrequency ablation, and 1 palliative supportive treatment. Clinicopathologic features and prognosis of 103 cHCC-CC patients after liver resection were compared with those of 6,679 patients with hepatocellular carcinoma (HCC) and 386 patients with intrahepatic cholangiocarcinoma (ICC) who underwent liver resection during the same period.
Results: The proportion of cHCC-CC in primary liver cancers was 1.5 %. The 103 cases of cHCC-CC were characterized by male predominance, infection with hepatitis virus or presence of liver cirrhosis, and elevated alfa-fetoprotein-findings similar to HCC. However, serum CA19-9 elevation, incomplete capsules, and lymph node involvement were similar to ICC. The 1-, 3-, and 5-year overall survival rates after liver resection were 73.9, 41.4, and 36.4 %, respectively, for patients with cHCC-CC versus 77.5, 53.3, and 41.4 % for HCC patients, and 58.0, 29.1, and 22.3 % for ICC patients (χ(2) = 137.5, P < 0.001). Tumor, node, metastasis system stage (hazard ratio 1.27, 95 % confidence interval 1.08-1.49, P = 0.003) and radical liver resection (hazard ratio 0.31, 95 % confidence interval 0.14-0.68, P = 0.004) were independent prognostic factors for overall survival.
Conclusions: cHCC-CC has biological behavior and prognosis that are intermediate between HCC and ICC. Radical liver resection can provide a better outcome for this uncommon malignancy.
Similar articles
-
Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5. Hepatobiliary Pancreat Dis Int. 2007. PMID: 17374575
-
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021. Int J Med Sci. 2021. PMID: 33390787 Free PMC article.
-
Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.J Hepatobiliary Pancreat Surg. 2006;13(6):537-42. doi: 10.1007/s00534-006-1117-1. Epub 2006 Nov 30. J Hepatobiliary Pancreat Surg. 2006. PMID: 17139428
-
Management of combined hepatocellular and cholangiocarcinoma.Int J Clin Pract. 2008 Aug;62(8):1271-8. doi: 10.1111/j.1742-1241.2007.01694.x. Epub 2008 Feb 13. Int J Clin Pract. 2008. PMID: 18284443 Review.
-
Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.World J Gastroenterol. 2022 Nov 7;28(41):5968-5981. doi: 10.3748/wjg.v28.i41.5968. World J Gastroenterol. 2022. PMID: 36405111 Free PMC article. Review.
Cited by
-
Radiofrequency ablation versus liver resection and liver transplantation for small combined hepatocellular-cholangiocarcinoma stratified by tumor size.Langenbecks Arch Surg. 2023 Mar 15;408(1):119. doi: 10.1007/s00423-023-02858-9. Langenbecks Arch Surg. 2023. PMID: 36918430 Review.
-
Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study.World J Surg Oncol. 2022 Feb 28;20(1):60. doi: 10.1186/s12957-022-02536-y. World J Surg Oncol. 2022. PMID: 35227269 Free PMC article.
-
Surgical Strategies for Combined Hepatocellular-Cholangiocarcinoma (cHCC-CC).Cancers (Basel). 2023 Jan 26;15(3):774. doi: 10.3390/cancers15030774. Cancers (Basel). 2023. PMID: 36765731 Free PMC article. Review.
-
A multidimensional nomogram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepatocellular cholangiocarcinoma.Ann Transl Med. 2021 Oct;9(20):1518. doi: 10.21037/atm-21-2500. Ann Transl Med. 2021. PMID: 34790724 Free PMC article.
-
Atypical hemangioma mimicking mixed hepatocellular cholangiocarcinoma: Case report.Medicine (Baltimore). 2017 Dec;96(50):e9192. doi: 10.1097/MD.0000000000009192. Medicine (Baltimore). 2017. PMID: 29390333 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical